NeoGenomics initiated with an Outperform at Leerink. Leerink analyst Puneet Souda started NeoGenomics with an Outperform rating and $18 price target. The analyst believes the company is a “uniquely” positioned one-stop shop oncology testing service provider with faster turnaround times versus its competition and a tech-only model that has helped it grow to the current levels. Souda projects NeoGenomics to deliver a 13% sales CAGR and about 25% adjusted EBITDA growth over the longer-term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.